Cerus Corporation (CERS) Financials
CERS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 197.7 million | 144.3 million |
2023-09-30 | 205.8 million | 156.8 million |
2023-06-30 | 198.9 million | 147.2 million |
2023-03-31 | 209.3 million | 149.8 million |
CERS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -15.0 million | 4.9 million |
2023-09-30 | -13.1 million | 4.0 million |
2023-06-30 | -9.4 million | 5.7 million |
2023-03-31 | -10.0 million | 5.7 million |
CERS Net Income
No data available :(
CERS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 65.9 million | - | 16.2 million |
2023-09-30 | 79.0 million | - | 16.4 million |
2023-06-30 | 84.5 million | - | 16.6 million |
2023-03-31 | 94.7 million | 54.8 million | 17.1 million |
CERS Shares Outstanding
CERS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 6000 | 13.6 million | 17.3 million | - |
2023-09-30 | 2.6 million | 16.8 million | 16.2 million | - |
2023-06-30 | 444000 | 19.2 million | 20.5 million | - |
2023-03-31 | 1.5 million | 17.4 million | 21.6 million | - |
CERS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 46.8 million | 21.5 million |
2023-09-30 | 39.8 million | 18.0 million |
2023-06-30 | 38.9 million | 17.5 million |
2023-03-31 | 31.0 million | 13.7 million |
CERS
Price: $1.71
52 week price:
Earnings Per Share: -0.22 USD
P/E Ratio: -8.78
Exchange: NGM
Sector: Healthcare
Industry: Medical Devices
Volume: 1.8 million
Ebitda: -11.8 millionMarket Capitalization: 317.2 million